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The study of alterations of tumor metabolism should allow the identification of new targets for innovative anticancer
strategies.Metabolic alterations are generally established in vitro, and conclusions are often extrapolated to the in vivo
situation without further tumor metabolic phenotyping. To highlight the key role of microenvironment on tumor
metabolism, we studied the response of glycolytic and oxidative tumor models to metabolic modulations in vitro and
in vivo. MDA-MB-231 and SiHa tumor models, characterized in vitro as glycolytic and oxidative, respectively, were
studied. Theoretically, when passing from a hypoxic state to an oxygenated state, a Warburg phenotype should
conserve a glycolytic metabolism, whereas an oxidative phenotype should switch from glycolytic to oxidative
metabolism (Pasteur effect). This challenge was applied in vitro and in vivo to evaluate the impact of different oxic
conditions on glucose metabolism. 18F-fluorodeoxyglucose uptake, lactate production, tumor oxygenation, and
metabolic fluxes were monitored in vivo using positron emission tomography, microdialysis, electron paramagnetic
resonance imaging, and 13C-hyperpolarizated magnetic resonance spectroscopy, respectively. In vitro, MDA-MB-231
cells were glycolytic under both hypoxic and oxygenated conditions, whereas SiHa cells underwent a metabolic shift
after reoxygenation. On the contrary, in vivo, the increase in tumor oxygenation (induced by carbogen challenge) led to
a similar metabolic shift in glucose metabolism in both tumor models. The major discordance in metabolic patterns
observed in vitro and in vivohighlights that any extrapolation of in vitrometabolic profiling to the in vivo situation should
be taken cautiously and that metabolic phenotyping using molecular imaging is mandatory in vivo.
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Enhanced glycolysis has for a long time been recognized as a common
metabolic feature of cancer [1–3]. Otto Warburg identified in the
1920s the presence of a faster glycolytic flux in tumor cells [4],
characterized by a high glucose uptake and increased lactate
production even in the presence of oxygen. Despite a limited
capacity for ATP production, aerobic glycolysis confers a major
advantage to tumor cells by supporting proliferation and biomass
production [3,5,6]. During decades, the loss of coupling between
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has been assigned to major mitochondrial dysfunctions [7]. However,
new evidence of oxidative activities in tumor cells has challenged this
paradigm [8–12]. Indeed, some tumor cells majorly rely on OXPHOS
for energy production, and besides the Warburg and oxidative
phenotypes, some cancer exhibits hybrid phenotypes with an acquired
metabolic flexibility.
Tumor metabolic alterations recently emerged as enticing targets
for the development of anticancer treatments [13–16]. To identify
potential treatment strategies, the specific descriptions of biochemical
pathways and metabolic alterations are commonly carried out in
well-established tumor models via in vitro phenotyping, which
provides specific tests that can define distinct metabolic profiles.
In vivo tumor models are then generally selected based on these
in vitro characterizations and used for preclinical studies before
clinical translation. Because in vitromodels do not reflect the complex
structure and the metabolic heterogeneity of tumors, numerous
factors could potentially be underestimated when translating the
models from in vitro to in vivo. Vascularization, cell density,
metabolic competition, cooperation, and commensalism with host
cells could indeed contribute to the metabolic pattern exhibited by
tumor cells.
Because some reports highlighted the potential influence of tumor
environment on metabolic profile of cancer cells [17,18], the
objective of the present study was to investigate if tumor models
differ in their metabolic phenotypes in vitro and in vivo. To answer
this question, a global metabolic study was carried out in vitro and
in vivo using prototypical tumor models. The MDA-MB-231 human
breast cancer model and the SiHa human cervical cancer model were
selected based on a previous in vitro study describing the cell lines as
glycolytic and oxidative, respectively [19]. Glucose metabolism was
analyzed under hypoxic and oxygenated conditions. According to a
paradigm extensively applied in vitro, we hypothesized that when
passing from hypoxia to a better oxygenated state, a Warburg
phenotype should conserve a glycolytic behavior, whereas an oxidative
phenotype should metabolically switch from glycolysis to OXPHOS
(Pasteur effect). Advanced imaging techniques including positron
emission tomography (PET), electron paramagnetic resonance (EPR)
imaging, and 13C-hyperpolarizated magnetic resonance spectroscopy
(MRS) were used to characterize the metabolic phenotype in vivo.
Our results identified major discordances between metabolic profiles
determined in vitro and in vivo, highlighting the limitations of direct
extrapolation of in vitro findings to the in vivo situation.
Material and Methods
Cell Culture
MDA-MB-231 (human breast cancer) and SiHa (human cervix
squamous cell carcinoma) cell lines (American Type Culture
Collection) were routinely cultured in Dulbecco's modified Eagle's
medium containing 4.5 g/l of glucose supplemented with 10% fetal
bovine serum and 1% penicillin-streptomycin.
Metabolic Fluxes In Vitro
Glucose utilization and lactate production were measured from
supernatants of cultured cells under hypoxia or after reoxygenation.
Cells were seeded in six-well plates and incubated until 70% to 80%
confluence under hypoxic condition (1% O2). Before the initiation of
the experiment, the incubation medium was removed. Cells werequickly washed, and medium was changed to a low-glucose medium
without glutamine. The cells were returned in the incubator under
hypoxic condition. After 4 hours under hypoxia, supernatant of
cultured cells was sampled. Cells were then returned in the incubator
to remain under constant hypoxia for 24 hours or moved to aerobic
condition (21% O2) during 20 hours. At the end of the experiment, a
final sampling of supernatant was performed for each condition,
constant hypoxia or reoxygenation. The protocol is summarized in
Figure 1. The supernatants collected were deproteinized. Glucose and
lactate concentrations in samples were measured using specific
enzymatic assays on a CMA600 microdialysis analyzer (CMA
Microdialysis AB, Solna, Sweden).
Animal and Tumor Models
Animal studies were undertaken in accordance with Belgian and
the Université catholique de Louvain ethical committee regulations
(agreements number UCL/2010/MD/001 and UCL/2014/MD/
026). EPR imaging and hyperpolarized 13C-MRS experiments were
carried out in compliance with the Guide for the Care and Use of
Laboratory Animal Resources (National Research Council, 1996) and
approved by the National Cancer Institute (NCI) Animal Care and
Use Committee.
To establish subcutaneous tumor models, a total of 107
MDA-MB-231 cells or 107 SiHa cells, amplified in vitro, were
collected by trypsinization, washed three times with Hanks balanced
salt solution, and resuspended in 200 μl of a 1:1 mixture of Matrigel
(BD Biosciences) and Hanks balanced salt solution. For EPR
spectroscopy, PET/computed tomography (CT) imaging, and
microdialysis experiments, the tumor cells were inoculated subcuta-
neously into the right hind thigh of nude female NMRI mice (Janvier
Le Genest-Saint-Isle, France). For EPR imaging and hyperpolarized
13C-MRS experiments, the tumor cells were inoculated subcutane-
ously into the right hind thighs of athymic nude female mice supplied
by Frederick Cancer Research Center (Animal Production, Frederick,
MD). The mice were kept under standard housing and feeding
conditions. A total of 29 MDA-MB-231 tumors and 26 SiHa tumors
were scanned of this study. All the experiments were performed when
tumors reached 7 mm in diameter.
Tumor Metabolic Fluxes
To evaluate the effect of different oxic conditions on tumor
metabolism, tumor-bearing mice were scanned twice for the
breathing challenge, air versus carbogen breathing, with 1 day
between each condition. The experimental design for in vivo
experiments is presented in Figure 2. Animals were anesthetized by
inhalation of isoflurane (Forene, Abbot, England) mixed with either
air (21% oxygen) or carbogen (5% CO2/95% oxygen), depending on
the breathing condition tested, in a continuous flow (2 l/min).
Animals were warmed (approximately 35°C) throughout the
anesthesia period, and breathing rate was maintained at 80 ± 10
breaths per minute using 1.5% to 2% isoflurane.
EPR Spectroscopy
In vivo tumor pO2 was monitored by EPR spectroscopy using
charcoal as the oxygen-sensitive probe [20,21]. EPR spectra were
recorded using a 1.1-GHz EPR spectrometer (Magnettech, Berlin,
Germany). According to calibration curves made by measuring the
EPR line width as a function of the pO2 [22], the EPR spectra line
width was converted to pO2. A charcoal suspension (100 mg/ml) was
Figure 1. In vitro metabolic fluxes. The impact of different oxic conditions on tumor cell metabolism was investigated.
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hours after EPR probe implantation [23]. For EPR readings, the
tumor under study was placed in the center of the extended loop
resonator whose sensitive volume extends 1 cm into the tumor mass.
pO2 measurements correspond to the average of pO2 values in the
tumor volume under study. For air condition, basal measurements
were performed. For carbogen condition, pO2 measurements were
started after a 10-minute inhalation period. Crossed conditions were
tested for the breathing challenge, the animal cohort was divided into
two groups, and the following conditions were tested: day 1 air/day 2
carbogen or day 1 carbogen/day 2 air. The details of the protocol are
presented in Figure 2A.
EPR Imaging
Tumor pO2 maps were obtained under air and carbogen breathing
using an EPR imaging scanner equipped with a volume leg coil
resonator tuned to 300 MHz. After the animal was positioned prone
with the tumor-bearing leg placed inside the resonator, the EPR
oxygen probe (OXO63, GE Healthcare) was injected intravenously as
a 1.125-mmol/kg bolus through a cannula placed in the tail vein.
EPR signals were obtained following the RF excitation pulses (60
nanoseconds, 80 W, 70° flip angle) using an analog-to-digital
converter (200 megasamples/s). The repetition time was 8 microsec-
onds. The free induction decay curves were collected under a nested
loop of the x, y, and z gradients, and each time point in the free
induction decay curve underwent phase modulation enabling
three-dimensional (3D) spatial encoding. Anatomical reference was
obtained using a 3-T magnetic resonance imaging (MRI) scanner
(MR Solutions, Guildford, UK). The imaging protocol is detailed in
Figure 2B. Co-registration of EPR and MRI images and data analysis
were accomplished using MATLAB software (Mathworks). From the
pO2 images of the tumor, pO2 frequency distributions and median
tumor pO2 were calculated.
PET/CT Imaging
Tumor 18F-FDG uptake was assessed during the breathing
challenge using PET/CT imaging. Whole-body PET imaging was
performed on a dedicated small-animal PET scanner (Mosaic, Philips
Medical Systems, Cleveland, OH) with a spatial resolution of 2.5 mm
(full width at half maximum). The PET scans were followed bywhole-body acquisitions using a helical CT scanner (NanoSPECT/
CT Small Animal Imager, Bioscan Inc., Washington DC). For each
breathing condition, anesthetized mice were injected 120 μl
intraperitoneally with 11.1 to 14.8 MBq of 18F-FDG (Betaplus
Pharma, Brussels, Belgium). A 10-minute transmission scan was first
obtained in a single mode using a 370-MBq 137Cs source for
attenuation correction. A 10-minute static PET acquisition was then
performed after a 60-minute resting period. After the correction with
attenuation factors obtained from the transmission scan, images were
reconstructed using a fully 3D row action maximum likelihood
algorithm in a 128 × 128 × 120 matrix, with a voxel size of 1 mm3.
After PET acquisition, anesthetized animals were transferred on the
same bed from the PET scanner to the CT scanner (x-ray tube
voltage: 55 kVp; number of projections: 180; exposure time 1000
milliseconds). The CT projections were reconstructed with a voxel size
of 0.221 × 0.221 × 0.221 mm3. The details of the imaging protocol are
presented in Figure 2A. Regions of Interest (ROIs) were delineated on
fused PET/CT images using PMOD software (PMOD, version 3.403,
PMOD Technologies Ltd., Zurich, Switzerland). Two-dimensional
ROIs were established on consecutive transversal slices using a 50%
isocontour tool (ROI including the pixel values larger than 50% of the
maximum pixel) that semiautomatically defined a 3D volume of
interest (VOI) around the tissue of interest. To avoid overestimation of
the uptake within the VOI, PET/CT fused images where used to
discriminate hot pixels coming from the neighboring tissues like urinary
bladder. Using the mean uptake within this VOI, the global tracer
uptake was assessed in tumors and expressed as percentage of injected
dose per gram of tissue (%ID/g). Crossed conditions were tested for the
breathing challenge, the animal cohort was divided into two groups, and
the following conditions were tested: day 1 air/day 2 carbogen or day 1
carbogen/day 2 air.
Microdialysis
For the evaluation of tumor extracellular lactate content during the
breathing challenge, we used microdialysis with a 6000-Da cutoff
probe (Aurora Borealis) and a saline solution flux of 1 μl/min. Two
probes were inserted per tumor under anesthesia 30 minutes before
the collection of dialysates. Three baseline samplings were performed
under air breathing. Then, the breathing gas was shifted to carbogen,
and sampling was initiated after a 10-minute equilibration period
Figure 2. Experimental design built as a dynamic follow-up of the tumors during a breathing challenge. Tumor-bearing mice were scanned
twice for the breathing challenge, air (light gray) versus carbogen (dark gray) breathing, with 1 day between each condition. Animals were
anesthetized by inhalation of isoflurane mixed with either air (21% O2) or carbogen (95% O2/5% CO2), depending on the breathing
condition tested, in a continuous flow (2 l/min). Animals were warmed (approximately 35°C) throughout the anesthesia period. Anesthesia
period is indicated by black lines. Breathing conditions are represented by light gray and dark gray shaded area for air and carbogen,
respectively. (A) EPR spectroscopy and PET scan experiments. Crossed conditions were tested (conditions tested: day 1 air/day 2
carbogen or day 1 carbogen/day 2 air). (B) EPR imaging. (C) Microdialysis experiments. (D) Hyperpolarized 13C-MRS studies.
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determined using specific enzymatic assays on a CMA600microdialysis
analyzer (CMA Microdialysis AB, Solna, Sweden). The experimental
design is displayed in Figure 2C.
Hyperpolarized 13C-MRS Studies
1-13C pyruvic acid (30 μl), containing 15 mM OXO63 and
2.5 mM gadolinium chelate ProHance (Bracco Diagnostics, Milano,
Italy), was hyperpolarized at 3.35 T and 1.4 K using the Hypersense
DNP polarizer (Oxford Instruments, Abingdon, UK) according tothe manufacturer's instructions. After 60 to 90 minutes, the
hyperpolarized sample was rapidly dissolved in 4.5 ml of a
superheated alkaline buffer that consisted of 50 mM Tris(hydrox-
ymethyl) aminomethane, 75 mM NaOH, and 100 mg/l of
ethylenediaminetetraacetic acid. The hyperpolarized 1-13C pyruvate
solution (96 mM) was intravenously injected through a catheter
placed in the tail vein of the mouse (12 μl/g body weight).
Hyperpolarized 13C-MRS studies were performed on a 3-T scanner
(MR Solutions, Guildford, UK). A home-built 13C solenoid leg coil
17.5 mm in diameter and 18.5 mm in length was used to closely
Figure 3. Metabolic behavior of MDA-MB-231 and SiHa cells under hypoxic and oxygenated conditions in vitro. (A) Under hypoxic
condition (1% O2), MDA-MB-231 cells produce high levels of lactate compared with SiHa cells. Under oxygenated condition (21% O2),
MDA-MB-231 cells maintained their glycolytic behavior. Data are expressed as means ± SEM. Unpaired tests were two-sided. (B) Effect
of reoxygenation on lactate production and on glucose utilization in MDA-MB-231 cells and SiHa cells in vitro. SiHa cells are more
sensitive to reoxygenation than MDA-MB-231 cells. Data are expressed as means ± SEM. Paired tests were two-sided.
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injection of hyperpolarized 1-13C pyruvate, spectra were acquired
every second for 240 seconds using a single pulse sequence. Data were
analyzed in a model-free approach using the lactate/pyruvate ratio,
calculated from the areas under the curves of the 1-13C lactate peak
and the 1-13C pyruvate peak [24]. Additional details about the
experimental design are presented in Figure 2D.
Statistical Analysis
Analysis was performed using the GraphPad Prism 6 software.
Results are expressed as means value of parameter ± SEM. All
statistical tests were two-sided. Paired t test was used to compare
mean changes between groups (air versus carbogen) for each tumor
model, and unpaired t test was used to compare mean changes
between the two tumor models. Results with P b .05 (*), b.01 (**),
or b.001 (***) were considered to be statistically significant.Results
In Vitro, MDA-MB-231 Cells Exhibit a Glycolytic Behavior
Even After Reoxygenation, Whereas SiHa Cells Are Oxidative
Under Oxygenated Condition
To assess the impact of different oxic conditions on tumor
metabolism, we first evaluated the cellular metabolic fluxes under
hypoxic and oxygenated conditions. Cells were kept during 4 hours
under hypoxia (1%O2) before undergoing reoxygenation (21%O2) or
remaining under constant hypoxia. Glucose utilization and lactate
production were measured during the reoxygenation period or during
the same period under hypoxia (n = 3 per model, triplicates) (Figure 3).
Under hypoxic condition (Figure 3A, 1% O2), MDA-MB-231 cells
produced high levels of lactate (5.76 ± 0.26 mM) compared with SiHa
cells (3.93 ± 0.29 mM) (P b .001), but similar glucose consumption
wasmeasured inMDA-MB-231 cells (2.80 ± 0.43mM) and SiHa cells
Figure 4. Effect of a breathing challenge on tumor oxygenation in vivo. These results show that hypoxic and oxygenated conditions are
achieved under air and carbogen breathing, respectively, in MDA-MB-231 and SiHa tumors. (A) Changes of mean pO2 under air and
carbogen breathing measured by EPR spectroscopy. Data are expressed as means ± SEM. Paired tests were two-sided. (B) pO2
frequency distributions in MDA-MB-231 and SiHa tumors as measured on EPR oxygen images. Lines indicated median pO2 values for the
collected data. (C) Representative EPR oxygen images of MDA-MB-231 and SiHa tumors obtained under air and carbogen breathing using
EPR imaging. Region of interest was drawn on the tumor zone.
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(Figure 3A, 21% O2), glucose utilization was significantly different
(P = .0034) between for MDA-MB-231 cells (2.55 ± 0.11 mM)
and SiHa cells (1.14 ± 0.39 mM). Also, MDA-MB-231 cells
produced more lactate (3.65 ± 0.22 mM) than SiHa cells (1.25 ±
0.17 mM) (P b .001).
To highlight a metabolic shift under different oxic conditions, we
compared the metabolic fluxes of each cell line under hypoxic and
oxygenated conditions (Figure 3B). By evaluating the variation of
glucose utilization or lactate production under hypoxic and oxygenated
conditions in each cell line, we noted that the reoxygenation majorly
impacted SiHa compared with MDA-MB-231 cell metabolism.
Indeed, for lactate production, MDA-MB-231 cells exhibit a decrease
of 37% (P b .001) compared with a decrease of 68% observed in SiHa
cells (P b .001). Glucose utilization was slightly but not significantly
decreased by 9% in MDA-MB-231 cells (P = .5710) and by 45% in
SiHa cells (P = .1300).
Even after reoxygenation, MDA-MB-231 cells remained more
glycolytic than SiHa cells. Our results are consistent with previous
phenotyping studies reporting MDA-MB-231 and SiHa cells as
Warburg [19,25] and oxidative, respectively [19,26].MDA-MB-231 and SiHa Tumors Are Hypoxic Under Air
Breathing and Are Reoxygenated Under Carbogen Breathing
To evaluate the metabolic behavior of these tumor cells in vivo, we
designed experiments to study the global metabolism in vivo before and
after reoxygenation induced by carbogen breathing. By changing O2
availability in the tumor during the breathing challenge, we expected to
achieve a hypoxic versus better oxygenated status in the models, thus
mimicking the hypoxic versus oxygenated conditions tested in vitro.
In Figure 4, the effects of the breathing challenge on oxygenation
were evaluated by EPR oximetry. Oxygenation increased after
carbogen breathing in MDA-MB-231 (n = 16, P b .001) and in
SiHa (n = 12, P b .001) tumors (Figure. 4A). Basal pO2 values (air
breathing) assessed by EPR spectroscopy were 3.8 ± 0.2 mm Hg for
MDA-MB-231 tumors and 4.9 ± 0.3 mm Hg for SiHa tumors.
Under carbogen breathing, MDA-MB-231 and SiHa tumors reached
a pO2 of 9.9 ± 0.95 mm Hg and 16.0 ± 2.3 mm Hg, respectively.
These data were confirmed by EPR imaging measurements
(MDA-MB-231: n = 3; SiHa: n = 5) (Figure 4, B and C). Typical
pO2 maps (Figure 4C) highlighted hypoxic tumors (pO2b 10 mm
Hg) under air breathing and a change of oxygenation after carbogen
breathing. pO2 frequency distributions were generated (Figure 4B)
Figure 5. Metabolic behavior of MDA-MB-231 and SiHa tumors under air and carbogen breathing in vivo. The biomarkers tested were
18F-FDG uptake, extracellular lactate content during microdialysis experiments, and the transformation of pyruvate into lactate using
hyperpolarized 13C-MRS. MDA-MB-231 and SiHa tumors exhibit the same phenotype under air (A) and also under carbogen (B) breathing.
Data are expressed as means ± SEM. Unpaired tests were two-sided. The magnitude of response to the breathing challenge (variation)
(C) is identical in both models. Data are expressed as means ± SEM. Unpaired tests were two-sided.
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Median pO2 shifted from 2.6 to 6.5 mm Hg in MDA-MB-231
tumors and from 2.0 to 13.7 mm Hg in SiHa tumors.
These results demonstrate that hypoxic and oxygenated conditions
are achieved under air and carbogen breathing, respectively, in both
tumor models.
In Vivo, MDA-MB-231 and SiHa Tumors Exhibit the Same
Phenotype Under Basal Condition and Under Carbogen
Breathing
To evaluate the metabolic behavior of the models in vivo, glucose
uptake, extracellular lactate content, and lactate flux were measured inMDA-MB-231 and SiHa tumors under air (hypoxic condition) and
carbogen (oxygenated condition) breathing (Figure 5).
Under air breathing, we observed a similar glycolytic behavior in
MDA-MB-231 and in SiHa tumors, assessed by a high uptake of
18F-FDG, high lactate content (evaluated by microdialysis), and high
lactate/pyruvate ratio (measured during hyperpolarized 13C-MRS
studies) (Figure 5A). Under carbogen breathing, there was no
appreciable difference in the metabolic profile of the two models
(Figure 5B). However, a metabolic shift was observed after
reoxygenation using carbogen in MDA-MB-231 and SiHa tumors.
As presented in Figure 6, 18F-FDG uptake was significantly reduced
in both models under carbogen (MDA: n = 16, P b .001; SiHa n =
Figure 6. Representative 18F-FDG PET images showing MDA-MB-231 and SiHa tumor-bearing mice imaged under air and carbogen
breathing. Tumors are indicated by thin arrows. 18F-FDG uptake is expressed in %ID/g. Images were normalized. 18F-FDG uptake drops
after carbogen breathing in MDA-MB-231 and SiHa tumors.
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cantly decreased under carbogen (MDA: n = 4, P = .0162; SiHa
n = 4, P = .0021). This metabolic shift was also noted by measuring
the conversion of pyruvate to lactate in the models (Figure 7) but did
not reach a statistical significance (MDA: n = 6, P = .0652; SiHa
n = 5, P = .3913). We also evaluated the magnitude of response to
the breathing challenge by measuring the variation of these biomarkers
between air and carbogen breathing conditions (Figure 5C). According to
all the biomarkers tested, there was no difference in behavior between
MDA-MB-231 and SiHa tumors during the breathing challenge
(P N .05).
Together, the results obtained in vivo indicate that the
MDA-MB-231 tumors do not appear more glycolytic than SiHa
tumors, both models exhibiting the same metabolic behavior under
the different conditions tested.
Discussion
This study emphasizes a major limitation of describing the metabolic
phenotype of tumors based on the in vitro studies solely. By
evaluating glucose metabolism under different oxic conditions in two
well-established glycolytic and oxidative tumor cell models, we
challenged the Warburg and Pasteur effects, respectively. In the
Warburg cellular model, in which metabolism is O2-independent, weexpected to preserve high rate of glycolysis even in the presence of
oxygen, whereas in the oxidative cellular model, in which metabolism
is sensitive to O2, we expected to observe a switch from glycolysis to
OXPHOS in the presence of a large amount of O2 relative to baseline.
This paradigm, extensively applied in vitro, has to our knowledge
never been applied so far in vivo. By applying protocols with hypoxic
and oxygenated conditions in vitro and in vivo, we identified a major
difference in the metabolic behavior between both experimental
conditions. In vitro, MDA-MB-231 cells kept their glycolytic
metabolism even after reoxygenation (typical of a Warburg
phenotype). On the contrary, SiHa cells shifted to an oxidative
metabolism when oxygen became available, which is consistent with a
Pasteur effect (Figure 3). The metabolic behavior was dramatically
different in vivo for both tumor models: MDA-MB-231 tumors and
SiHa tumors exhibited the same phenotype under hypoxia, and no
difference was observed between both tumor models after reoxygen-
ation induced by the carbogen breathing (Figure 5). These results
highlight that the tumor microenvironment could be as important as
the (epi)genetic profile to shape the tumor phenotype.
Our work extends recent efforts highlighting the limitation of
in vitro studies to truly reflect the complex tumor behavior. Even if
the microenvironment has already been presented as a decisive
parameter determining the metabolic phenotype of tumors
Figure 7. Typical 13C-MRS spectra from representative MDA-MB-231 tumors and SiHa tumors and corresponding 1H anatomical images.
Lactate production, measured by the Lac/Pyr ratio, is reduced in MDA-MB-231 and SiHa tumors after carbogen breathing: pyruvate (173
ppm), lactate (185 ppm) peaks, and pyruvate hydrate (181 ppm).
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alterations in cancer, and only a few studies have addressed the
influence of the in vivo environment on the tumor metabolism.
Davidson and colleagues recently investigated tissue metabolites from
non–small cell lung tumors after the infusion of [U-13C]glucose and
[U-13C]glutamine in mice [18]. Although lung cancer cells exhibited
minor glucose oxidation in vitro, they established that glucose
oxidation was required for tumor growth in vivo. Also, these authors
identified a limited glutamine metabolism in lung tumor in vivo
compared with lung cancer cells in vitro and suggested lactate as
another preferred source of carbon in lung tumors. They also assessed
that transplanted tumors exhibit a phenotype more similar to
spontaneous lung tumors in mice compared with tumor cells in
culture, highlighting the importance of model selection. In another
recent study of Hensley and coworkers [17], metabolic activities
related to perfusion were studied in human lung tumors based on
multimodality imaging and 13C-glucose infusions. Poorly perfused areas,
assessed by dynamic contrast-enhanced MRI, exhibited higher glucose
metabolism compared with well perfused areas that preferentially relied
on alternative fuels. Both these studies performed in lung cancer were
able to identify commonmetabolic features in preclinical models and in
patients, showing minimal resemblance with in vitro characterization.
Our present work adds to these studies in several ways. First, we
showed that tumor cell models exhibit distinct metabolic behaviors
in vitro but present the same behavior in vivo as attested by a
multimodality imaging study. Although we reproduced similarexperimental conditions in vitro and in vivo, we assessed that the
paradigm, extensively applied in vitro, did not recapitulate the in vivo
behavior of these models. The results observed in vivo could not be
attributed to the impact of anesthesia on tumor hemodynamics as it
was demonstrated previously that isoflurane had negligible effect on
both tumor perfusion and oxygenation [29]. Also, the measurement
repeatability was demonstrated during EPR spectroscopy and PET
scan experiments. Indeed, crossed conditions were tested for the
breathing challenge, and no difference was observed between the two
subgroups in the animal cohort. Second, we assessed the occurrence
of a rapid metabolic adaptation after carbogen breathing in vivo in
both models. Carbogen breathing had a significant impact on
18F-FDG uptake and lactate content (Figure 5). This demonstrates
the rapid plasticity of tumor cells to adapt their metabolism to the
oxygen environment, a phenomenon known as the Pasteur effect. As
already suggested by other studies [30,31], our data support that
careful experimental protocol optimization is required for metabolic
studies, likewise breathing conditions. However, regardless of the
breathing gas used, the evaluation of tumor oxygenation in parallel to
tumor metabolism studies would undoubtedly improve tumor
phenotyping research. Third, the advanced imaging technologies
used in the present study represent relevant tools for tumor metabolic
phenotyping in vivo. 18F-FDG PET scan is a widespread technology
already used in clinical routine, and hyperpolarized 13C-MRI is an
emerging technology that was recently introduced in clinical research
[32]. Our data suggest that molecular imaging techniques could
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and may be used as relevant biomarkers to guide treatments targeting
tumor metabolism.
However, our study presents some limitations that should be
addressed. First, host cells and tumor microenvironment could be
involved in the divergence of metabolic metabolism between in vitro
and in vivo studies. In our study, the metabolic profile was established
in vivo considering results on the whole tumor. Using a global
measurement of the tumor mass, we were not able to discriminate
between host cell metabolism and cancer cell metabolism. Further
investigations using co-culture models under different culture
conditions should be considered to determine the role of host cell
in metabolic profile measurements as well as the impact of nutrient
availability, oxygenation, and acidification on tumor metabolism.
Second, xenografts using immortalized cell lines represent the
majority of the tumor models investigated due to their easy use.
Nevertheless, this approach does not always correlate with clinical
outcomes in patients, as the generation of cancer cell lines could
majorly alter biologic and genetic properties and cause the loss of
specific cell population. Third, the use of immunodeficient animals
provides a less realistic tumor microenvironment. Therefore, it would
be important to further explore primary cell cultures implanted in
immunocompetent animals. Finally, comparative study involving
different implantations such as subcutaneous or orthotopic should be
considered.
In conclusion, our metabolic study identified distinct metabolic
behaviors of two well-established tumor models in vitro and in vivo.
Results suggest that there is a need to take cautiously any
extrapolation of in vitro characterization to the in vivo situation.
Implanted tumors and spontaneous cancer models should be
preferred to identify relevant metabolic alterations within the milieu
of the tumor microenvironment. When well-established tumor cell
models are translated in vivo, additional phenotyping should be
considered and could be achieved by using clinically relevant
biomarkers like 18F-FDG PET scan and hyperpolarized 13C-MRI.
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